Inozyme Pharma Inc（INZY）股票分析

$4.000

+0.010 (+0.25%)收盤時

Loading chart…

High: 4.000
Open: 4.000
VWAP: 4.00
Vol: 1.46M
Mkt Cap: 279.59M
Low: 3.990
Amount: 5.83M
EV/EBITDA, TTM: 0.09

Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics that target the pyrophosphate (PPi)-Adenosine Pathway, a key regulator of bone health and blood vessel function. Its lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, ENPP1 fusion protein that is designed to increase PPi and adenosine, to enable the potential treatment of multiple diseases caused by deficiencies in these molecules. The Company is conducting clinical trials of INZ-701 for the treatment of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency, ATP-Binding Cassette in the C6 family (ABCC6) Deficiency, and calciphylaxis. The Company also plans to investigate the potential of a next generation INZ-701 molecule to address posterior longitudinal ligament (OPLL).

www.inozyme.com

估值指標

The current forward P/E ratio for Inozyme Pharma Inc (INZY) is -0.81, compared to its 5-year average forward P/E of -2.54.

Forward P/E

Overvalued

5Y Average P/E

-2.54

Current P/E

-0.81

高估

-1.50

低估

-3.58

Forward EV/EBITDA

Overvalued

5Y Average EV/EBITDA

-0.95

Current EV/EBITDA

0.09

高估

0.06

低估

-1.96

Forward P/S

Strongly Undervalued

5Y Average P/S

0.00

Current P/S

0.00

高估

0.00

低估

0.00

事件時間軸

2025-10-07 (ET)

08:34:36

CervoMed Names Matthew Winton as Chief Commercial and Business Officer

2025-07-22 (ET)

08:30:11

Sixteen option delistings on July 22nd

2025-05-16 (ET)

13:26:28

Leerink bullish on BioMarin following Inozyme deal, expects additional BD

09:29:29

BioMarin says Inozyme deal to strengthen enzyme therapies portfolio

09:24:45

Inozyme downgraded to Neutral from Outperform at Wedbush

Show More Events

資訊

INZY FAQ — answered by Alphio AI

Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics that target the pyrophosphate (PPi)-Adenosine Pathway, a key regulator of bone health and blood vessel function. Its lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, ENPP1 fusion protein that is designed to increase PPi and adenosine, to enable the potential treatment of multiple diseases caused by deficiencies in these molecules. The Company is conducting clinical trials of INZ-701 for the treatment of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency, ATP-Binding Cassette in the C6 family (ABCC6) Deficiency, and calciphylaxis. The Company also plans to investigate the potential of a next generation INZ-701 molecule to address posterior longitudinal ligament (OPLL). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。